



Biofilm Formation Capability of Clinical *Helicobacter pylori* Isolates on MKN-45 Cells

Bahareh Attaran ^{1,2,*}, Tahereh Falsafi ¹ and Mahboubeh Kabiri ³

¹Department of Microbiology, Faculty of Biological Sciences, Alzahra University, Tehran, Iran

²Research Center for Applied Microbiology and Microbial Biotechnology; Alzahra University, Tehran, Iran

³Department of Biotechnology, College of Science, University of Tehran, Tehran, Iran

*Corresponding author: Department of Microbiology, Faculty of Biological Sciences, Alzahra University, Tehran, Iran. Email: b.attaran@alzahra.ac.ir

Received 2021 May 17; Revised 2021 June 22; Accepted 2021 June 23.

Abstract

Background: In vitro biofilm formation of *H. pylori* is demonstrated; however, its potential role in the persistent infection of the human stomach has not yet been addressed.

Objectives: The aim of this study was to assess the biofilm formation of clinical *H. pylori* isolates on an epithelial cell line, a line that produces mucin.

Methods: *H. pylori* isolates consisting of an efficient (19B) and a weak (4B) biofilm formation ability, were selected from screening of the clinical isolates. Their adhesion index was determined after 2 h incubation with the semi-confluent monolayers of MKN-45 cells. Their biofilm formation was evaluated after 24 and 72 h incubation with MKN-45 cells using a modified adherence assay developed in this work. Production of biofilm was quantitatively assessed by CFU enumeration and qualitatively by the immunofluorescence, and scanning-electron-microscopic (SEM) methods. Due to the importance of mucin in the binding of *H. pylori* and biofilm formation, the binding strength of the mucin binding protein, MUC5AC, and MUC1 with docking was investigated using cluspro webserver.

Results: Using MKN-45 epithelial cell line as a model, significant differences were observed between the adhesion index of 19B and 4B isolates. After 24 h, both isolates were able to form biofilms with significantly higher numbers of CFU for the 19B isolate. These results were confirmed by immunofluorescence and SEM such that after 24 h, a cluster of coccoid bacteria on the MKN-45 cells in the form of microcolonies was observed. The docking results showed that MUC5AC demonstrated the most favorable interaction with *H. pylori* urease and BabA with docking energy scores of -931.1 and -906.3 kcal.mol⁻¹, respectively.

Conclusions: By developing an appropriate in situ biofilm assay, we investigated biofilm formation by clinical *H. pylori* isolates on the MKN-45 epithelial cell line. The establishment of such an in-situ model for studying the biofilm formation ability of clinical isolates can also be used to study cell-bacteria interactions in the context of a complex biofilm and also as a model for drug screening applications.

Keywords: *Helicobacter pylori*, MKN45 Cell Line, Adherence, Biofilm, Coccoid Form

1. Background

Over one half of the world's population is colonized with *Helicobacter pylori*. Hence it is considered as one of the most frequent agents of human infections (1).

Adhesion to gastric cells is a crucial step in the formation of a successful infection because it provides protection from natural clearance mechanisms (2). In spite of the fact that many investigations have been performed to understand the role of virulence factors in favoring the more severe outcome of *H. pylori* infection, it is not well known why this infection still persists in the absence of fatal outcome for years and lead to a chronic infection.

The first study investigating in vitro biofilm formation

by *H. pylori* corresponds to the work of Stark et al. (3), which was followed by other investigators (4-8). Very few in vivo studies have been undertaken, and they are limited to the observation of biopsy specimens from the patients' stomach (9, 10). In light of growing evidence, revealing the impacts of biofilm on antibiotic action and host immune responses, the importance of the biofilm formation ability of *H. pylori* is increasingly being recognized.

In prior studies, the ability of different *H. pylori* strains in vitro models on an abiotic surface such as polystyrene or glass has approved the biofilm formation ability of this bacterium, but those surfaces did not mimic the real state of stomach surface. Using the C57BL/6J mice model, we

have previously studied the ability of *H. pylori* to form typical biofilms in the mouse stomach mucosa, but animal models have some limitation such as cost, ethical rules, and hard to set up (11, 12). Multiple investigators have studied the advantages of an in-situ system for studying biofilm formation by bacteria. In a recent report, Salas-Jara et al. (13) have studied the ability of *Lactobacillus fermentum* UCO-979C to form biofilm on cell line. The cell line culture method was also used as model for human skin wound. Using histological assessment, wide-field fluorescence microscopy, stereo-fluorescence microscopy, and SEM, Ashrafi et al. (14), showed the biofilm formation on cell lines.

In vitro evaluation of *H. pylori* adherence to epithelial cell models using microtiter-plates and adherence assessment by calculating the adhesion index are now well defined. However, these tests can only demonstrate the interaction of the bacteria with the host cells under a short period and are not sufficient to demonstrate the biofilm formation.

2. Objectives

The objective of present study was to assess the biofilm formation of clinical isolates of *H. pylori* on the human epithelial cell model MKN-45 cell-line, a line that produces the mucin. For this purpose, an in-situ assay was developed with two advantages: first, to permit development of a biofilm in-situ; second, the presence of mucin, which is present in real conditions in the stomach and gastrointestinal tract. As mucin could play a critical role in the colonization of *H. pylori*, in this study, we investigated the interaction of adhesive factors with mucin using bioinformatics tools.

3. Methods

3.1. Bacterial Isolates and Growth Conditions

A collection of thirty clinical *H. pylori* isolates, isolated from patients showing signs of chronic gastritis, were taken with informed consent for this study. Isolates were cultured onto brucella agar base (Merck, Germany), supplemented with 5% defibrinated sheep blood and antibiotics at 37°C under microaerophilic atmosphere for 3 - 7 days.

The isolate were identified by Gram staining, biochemical tests, including catalase, oxidase, urease, and nitrate. As previously described, the molecular identity of *H. pylori* strains was confirmed by PCR amplification of gene 16sRNA and *glm* gene

(*glm*-F5'GGATAAGCTTTAGGGGTGTTAGGGG3', *glm*-R5' GCATTCAAACTTATCCCAATC 3', 16s rRNA-F 'GAAGATAAT-GACGGTATCTAAC 3', 16s rRNA-R5' ATTCACACCTGACTGAC-TAT 3') (15, 16).

3.2. In Vitro Screening of Biofilm Formation

It was done by a method adapted from a previously described protocol, with some modifications (7, 17, 18). The grown colonies were harvested from culture-plates and inoculated into brucella broth (Biolife, Italy) supplemented with 2% (w/v) fetal calf serum (FCS) and 0.3% (w/v) glucose (Merck, Germany), and incubated overnight at 37°C in the microaerophilic atmosphere with shaking at 100 rpm. An optical density of broth cultures adjusted to 0.2 at 600 nm (A600), equivalent to $5 - 8 \times 10^3$ CFU/mL, was inoculated (250 μ L) into the 96-well flat-bottomed culture plates (BIOFIL, Jet Bio-Filtration Products Co., China) and incubated at 37°C under the microaerophilic condition for six days. After biomass formation, non-adherent bacteria were removed by washing (3 \times) with sterile PBS. The tightly attached bacteria were fixed with 99% ethanol (200 μ L per well) for 20 min and air-dried. Plates were then stained with 1% crystal violet (200 μ L per well) for 5 min, and the excess stain was rinsed away with running tap water. The dried plates were treated with 33% (v/v) glacial acetic acid (160 μ L per well), and their optical density (OD) was measured at 505 nm by ELISA reader (SCO, Germany). The following criteria were used for biofilm classification in *H. pylori* clinical isolates: $OD \leq OD_{control}$ = Non-biofilm-former, $OD_{control} < OD \leq 2 \times OD_{control}$ = Weak biofilm-former, $2 \times OD_{control} < OD \leq 4 \times OD_{control}$ = Moderate biofilm former, $OD > 4 \times OD_{control}$ = Strong biofilm-former (19).

3.3. Epithelial Cell Line and Monolayers Preparation

The MKN-45 (IBRC C10137) cell line (Iranian Biological Recourse Center: IBRC) was routinely grown in RPMI1640 + 20% fetal bovine serum (FBS: Gibco, USA) and antibiotics including 40 μ g/mL gentamicin (sigma - USA) and 2.5 μ g amphotericin B per mL of media (Cipia, India).

3.4. Adherence Assay

The confluent cell culture was trypsinized, adjusted to $4 - 5 \times 10^5$ cells/ml, transferred into 12-well tissue culture plates (Orange Scientific), and incubated until approximately 106 cells/well. *H. pylori* 19B and 4B Isolates were grown for three days, and the negative control, *E. coli* ATCC

2995 isolate, was grown on LB agar plate overnight. Inoculums ($\times 10^9$ bacteria/mL) were prepared in PBS; their number was determined by the CFU method. Before inoculation, monolayers were washed and incubated with 0.9 mL RPMI medium + 3% FBS. The cells in the wells were counted and inoculated with the bacterial suspension at a ratio of 100 bacteria/host-cell (20) and incubated for 2 h. Then, the monolayers were vigorously washed (3 \times), and the cells (3 wells) were lysed by addition of 1 mL of deionized sterile water and incubated at 37°C for 30 min. The resulting suspension was used for enumeration of adherent bacteria by CFU method, and to obtain the adhesion index, three wells were trypsinized for enumeration of host cells by direct counting in a haemocytometer. The adhesion index was defined as the mean number of adhering bacteria per cell, which was obtained from at least three independent assays (21).

3.5. Evaluation of Biofilm Formation

Six-well culture plates were seeded with MKN-45 cells ($6 - 7 \times 10^5$ cells/well) in RPMI 1640 containing 20 % FBS and were grown for 3 - 7 days to 80% confluence by renewing their medium every day. *H. pylori* cultures were harvested into F-12 Ham nutrient medium (Sigma-Aldrich, USA) washed two times and adjusted to 10^9 bacteria/mL. Prior to bacterial-inoculation, medium was replaced with F-12 Ham medium supplemented with 5% FBS and 2.5 μ g/mL of amphotericin B, then inoculated with bacterial-suspension and incubated for 3 h. The wells were drained off, washed to eliminate planktonic bacteria, and incubated in fresh medium for 24 and 72 h, during which the medium was renewed two times a day. After each period, the wells were washed vigorously (3 \times), then treated with 0.1% Triton X-100 in PBS for 10 min to lyse the host-cells and disperse the biofilm. Serial dilutions of the lysate were used for enumeration of bacteria by the CFU method.

3.6. Biofilm Monitoring by Immunofluorescence Staining

Inoculated host-cells grown on microscopic chamber slides were washed 3 \times after incubation period (to eliminate planktonic-bacteria). Cells were fixed with 4% paraformaldehyde (25°C for 10 min), washed (3 \times) for 5 min with PBS-T (PBS- 0.05%, v/v Tween-20) to eliminate fixative traces and to permeabilize the cells. Cells were blocked with 3% BSA in PBS-T (1 h, 25°C), washed in PBS-T for 5 min and incubated with the diluted antibody (1:1000 in PBS-T + 1% BSA) of a home-made anti *H. pylori* antibody at 25°C for 1 h (22). They were washed (3 \times) with PBS-T (10 min) and incubated (1 h) with the goat anti-rabbit IgG conjugated to

rhodamine in PBS-T + 1% BSA (Sigma, USA) with a concentration of 0.01 μ g/mL, washed with PBS-T (3 \times) for 10 min. Also, nuclear staining was performed as follows: cells were stained with DAPI (4', 6-diamidino-2-phenylindole, Roche, Germany), diluted 1:1000 in PBS-T or PI (Propidium iodide, Molecular Probes) for 5 min, and then rinsed with PBS for another 5 min (23).

3.7. Biofilm Monitoring by Scanning Electron Microscopy

Samples were fixed in 2.5% glutaraldehyde for 30 min, dehydrated with increasing concentrations of ethanol (30, 50, 70, 90) and 100% (2 \times) each for 5 min. Samples were stored in desiccators until they were coated with gold-palladium sputter for two 200-seconds intervals (Nano Structured coating Co. Iran). Biofilm monitoring by scanning electron microscopy (SEM) micrographs were performed using TESCAN VEGA3S electron microscope at 30 KV (10).

3.8. Mucin and Mucus-Binding Proteins of *H. pylori* Interaction

In-silico interaction of mucus-binding proteins of *H. pylori* with mucins was assessed using Cluspro protein-protein Docking (24-27) which, is the fully automated, web-based program for the computational docking of protein structures. The docking algorithms evaluate billions of putative complexes; a filtering method by selecting those with good electrostatic and desolvation free energies for further clustering was applied. According to literature, MUC5AC and MUC1 were analyzed for their in-silico interaction with Lewis b antigen binding by the *H. pylori*-BabA and urease.

The three-dimensional structure of mucin-binding proteins and mucins were downloaded from the Protein Data Bank (PDB) database (<https://www.rcsb.org/>). 1e9z (crystal structure of *H. pylori* urease), 4zh7 (Lewisb antigen binding by the *H. pylori*- BabA), 5ajn (MUC5AC), 2acm (human mucin 1 (MUC1)), were used for docking analysis after removing solvent and ligands with UCSF Chimera (28). Individual docking procedures have been performed for each ligand-protein complex. The findings have been ranked in the order of rising docking energies which the lowest binding energy of each cluster was considered. Docked complexes were further analyzed by using UCSF Chimera visualization.

3.9 Statistics

Standard statistical analysis by Graph Pad Prism 7 was used to evaluate the reproducibility of the test in various

wells (standard deviations) and to determine the significant difference (P-value) between the adhesion index of 19B and 4B *H. pylori* isolates as well as ATCC 2995 *E. coli* isolate.

4. Results

4.1. Isolates Screening

All 30 isolates were able to form biofilm on polystyrene microplates, with differences between the amounts of biofilm among them. According to our result, 3.3% of isolates are strong biofilm former, 10% were weak biofilm former, and the rest were moderate biofilm former. Two isolates with the highest and lowest ability in biofilm formation, named (19B and 4B), were selected for further in-situ biofilm formation analysis on the epithelial cell line.

4.2. Adherence to MKN-45 cells

Evaluation of adhesion index after 2 h of incubation revealed that both isolates were able to adhere to MKN-45 cells. However, their adhesion indices were significantly different and were 12.9 and 9.6 for 19B and 4B, respectively. Negative-control, 2995 *E. coli* strain, could not adhere to MKN-45 cells.

4.3. Quantitative Evaluation of Biofilms

The number of bacteria recovered from lysed cells after 24 and 72 h incubation was counted. *H. pylori* isolate 19B produced significantly higher amount of biofilm on the host cells compared to the 4B isolate (Figure 1). The number of bacteria reduced by two folds in both isolates after 72 h.

4.4. Inverted Light Microscope Observation

Both spindle-shaped and oval cells growing in monolayers and single round cells or clumps in suspension were seen in inverted light microscope images (Appendix 1 in Supplementary File).

Microscopic analysis of crystal-violet-stained *H. pylori* isolate 19B biofilms on the MKN-45 cells indicated that cells aggregated together to form microcolonies (Figure 2). After 24 h, cells had begun to aggregate and form small groups (Figure 2B), and by 72 h, larger groups of microcolonies were evident (Figure 2C and D).

4.5. Immunofluorescence Observation of the Biofilms

Figure 3 shows the nuclear staining of the cells with propidium iodide but revealed no difference in the number of host cells between the control (Figure 3A) and those infected by the 19B (Figure 3B-C) and 4B isolates (Figure 3D).

Analysis of the immunofluorescence images after 24 h revealed the clusters of bacteria on the MKN-45 cells for both 19B and 4B isolates, with higher densities for the 19B isolate (Figures 4-5). After 72 h, the same clusters of bacteria were observed embedded in the extracellular matrix.

4.6. SEM Analysis of Biofilms

Observation of SEM images 24 h after incubation showed the cell cluster morphology of the cell-associated bacteria, in the form of microcolonies in which the bacterial cells were tightly associated (Figure 6). After 72 h, although the same microcolonies were detectable, a change in the morphology of MKN-45 cells was also observed, especially in the case of those associated with the 19B isolate (Figure 7).

4.7. Docking Analyzing Mucus Binding Proteins with Mucin

The in-silico docking results between the *H. pylori* mucin-binding protein and mucin (MUC1 and MUC5AC) revealed that MUC5AC has the highest binding affinity in terms of the protein-protein interaction. Out of the four possible interactions, MUC5AC demonstrated the most favorable interaction with *H. pylori* urease and BabA with a docking energy score of -931.1 and -906.3 kcal.mol⁻¹, respectively (Figure 8).

5. Discussion

Despite the fact that numerous studies confirmed biofilm formation by *H. pylori* on non-living environments, a few studies have been shown biofilm formation on humans stomach or other in vivo models. Recently, research has suggested the correlation between *H. pylori* biofilm and gastric cancer, but more evidence is required to confirm this matter (29). Nowadays, cell culture is considered as a rapid and inexpensive method for investigating the efficacy of drug candidates (30). Therefore, creating an in vivo model for biofilm assay will be useful for studying the relationship between biofilm and cancer and examining antibiotic resistance.

We developed an assay for exploring the biofilm formation by *H. pylori* via modifying the universal adherence test




Figure 1. Violin plot of bacterial enumeration in the *H. pylori* biofilms after 24 and 72 h.

to evaluate biofilm formation on a host cell model. Comparison of adherence index after 2 h, and evaluation of bacterial count after 24 h, showed a significant difference between isolates 19B and 4B (Figure 1). Thus, despite the suggestion that the 19B isolate has a higher capacity to proliferate on the host cells, a lower number of bacteria was detected after 72 h in both isolates, which might be due to the limitation of host-cell growth conditions and/or presence of non-viable bacteria.

Nuclear staining of the cells after 24 h showed no difference in the number of host cells between control and those infected by 19B and 4B isolates, suggesting that the host cells maintain their integrity after 24 h in all cases (Figure 3). However, evaluation of immunofluorescent images revealed a dense presence of fluorescent stained bacteria, which was higher for the 19B isolate (Figures 4-5).

Inconsistent with our result, Cai et al. (31) used AGS cell line culture to study *H. pylori* biofilm formation and examined the biofilm formation with a fluorescent microscope (live/Dead staining) but did not elaborate on their work.

By SEM evaluation, the communities of coccoid bacteria were observable on the host cells, for both isolates (Figures 6-7). The presence of bacterial cells on the extracellular matrix was also visible, especially after 72 h. Despite the persistence of microcolonies after 72 h of incubation, signs of host cell deterioration were noticeable in the SEM images, which might explain the decline in bacterial count

after 72 h. Previous studies have proposed that some *H. pylori* isolates are able to form a biofilm in laboratory in the form of coccoids (4).

Hathroubi et al. (32) used a method similar to ours. Additionally, they noticed in SEM images *H. pylori* totals were not homogeneously dispersed over the outside of the AGS cells yet discovered to a great extent in the recessed cell-cell intersection regions, as revealed previously. This non-uniformity can be seen to some extent in the images of this study (33).

Although several studies have indicated that biofilm formation plays an important role in the pathogenesis of chronic infection, these studies have been performed in vitro using solid surfaces such as glass or plastic, where it is not possible to completely imitate the real conditions of the stomach (4-6, 34).

Goblet cell increased release of secreted mucins to mucosal infection (35). Mucins are secreted cell surface glycoproteins which that some pathogenic bacteria have mechanisms to target specific surface mucins on the other hand; they act as inhibitors of the many bacterial receptors. It is also known that the adherence of *H. pylori* to the gastric mucosal surface constitutes a critical step in interactions with the host gastric cells and the first step in biofilm formation. Furthermore, it was known that the blood group antigen binding adhesin (BabA) of *H. pylori*, binds to Lewis b antigen. Gastric mucous layer gel, mainly consisting of




Figure 2. Representative inverted micrographs of biofilms formed by clinical isolate *H. pylori* isolate 19B on MKN-45 cell monolayer after staining with crystal violet for three minutes. Cell cluster morphology (microcolony) strongly suggestive of biofilm formation. A, Control group; B after 24 h; C and D, After 72 h (Scale bar, 200 μ m).

the MUC5AC that, harbors glycan-rich domains presenting the Lewis b antigen, which is the most important carrier of the LeB carbohydrate structure in normal gastric tissue (36, 37).

In addition to MUC5AC, MUC1 is the main mucin genes expressed in surface/foveolar epithelial cells in the normal stomach. *H. pylori* regulate mucin gene expression at the transcriptional level in gastric cells line (36). MUC1 is aberrantly overexpressed by more than 50% of stomach cancers. Still, its role in carcinogenesis remains to be defined, *H. pylori* upregulate MUC1 expression in gastric cancer cells (38).

Higher mucin expression in the gastric epithelium of *H. pylori* positive patients than in healthy controls was demonstrated (39). It was shown that in oral cavity *H. pylori* using BabA, SabA binds to salivary mucins in saliva, and it seems that affect that colonization in various niches along the orogastric infection route and reinfection (40).

In another study, it was shown that urease from *H. pylori* increases the expression of mucin gene including MUC5AC in AGS cell line, so docking urease with mucin was also investigated (36). In conclusion, the interplay between *H. pylori* infection and mucin secretion is important for attachment. *H. pylori* bind to gastric mucin. On the other hand, *H. pylori* infection increases its mucin expression. Therefore, mucin plays an important role in simulating the actual condition of the stomach and is important in studies related to *H. pylori* binding.

Since the presence of *H. pylori* has been reported in the subgingival biofilm, due to the importance of mucin in the binding of *H. pylori*, which is the first step in biofilm formation, this study, we also examined the binding strength by docking methods. As our results showed, *H. pylori* has the ability to bind to mucin, especially MUC5AC. Therefore, if the mucin is present in biofilm formation assay, the results of study will be close to the natural conditions.




Figure 3. Immunofluorescence image of biofilm formed after 24 h by 19B and 4B *H. pylori* on the MKN-45 cells with nuclei stained with propidium iodide. A, Control without *H. pylori* inoculation; B-C and D, Incubation with 19B and 4B isolates, respectively. Arrowhead shows biofilm formation over MKN-45 monolayer.

Matsuda et al. compare gene expression alteration after *H. pylori* infection in three cell lines, *H. pylori* infection, AGS, KATO III, and MKN45. They showed that *H. pylori* cells alter the expression of the transcription factors mRNA such as az, MUCs mRNA in *H. pylori*-infected cells, in a pattern common to cells. In AGS cells, the Intestinal phenotype is predominated, whereas the gastric phenotype predominated in MKN45 and KATO III cells. In MKN45 cells, *H. pylori*-induced the three MUCs mRNAs expression (41). Therefore, due to the fact that the expression pattern of mucins in MKN45 cell line is closer to the conditions of the stomach, this cell line was selected to study biofilm formation.

Cole et al. (5) showed that 10% mucin increased planktonic cells, but as they mentioned in that article, they autoclaved mucin with a medium before assay as mucins are glycoproteins probably lose native 3D structure and may

serve as a carbon source.

In contrast to this study, we showed that mucin was significantly effective in biofilm formation in our previous study. In our study, we used mucin from the porcine stomach (type II), which contains MUC2 (16). Therefore, it seems that the type of mucin and assessment method affect the results. More studies are needed to reach a definitive conclusion in this regard.

In the current examination, we attempted to emulate, to some extent, the real conditions of the stomach since the cell-line used in this work is able to produce a mucus-layer (42), which would be an advantage for this model to initiate bacterial attachment. Thus, to our knowledge, the present work is the first study, which evaluated the ability of clinical isolates of *H. pylori* to adhere and form a biofilm in an experimental human epithelial cell line, MKN-45 cell-model.




Figure 4. Immunofluorescence image of biofilms formed after 24 h by 19B and 4B *H. pylori* isolates on MKN-45 cells. A-B, Rhodamin stained control group visualized by red filter and nuclei stained by DAPI visualized by UV filter, respectively; C and D, Cells inoculated with 19B isolates stained with rhodamin and nuclei stained by DAPI; E and F, Cells inoculated with 4B isolate stained with rhodamin and nuclei stained by DAPI (Scale bar, 200 μ m).




Figure 5. Immunofluorescence image of biofilm formed after 72h by 19B and 4B *H. pylori* on the MKN-45 cells. A-B: control cell nuclei stained with DAPI. 72 hours-biofilm formed on MKN-45 cell monolayer, A, C, and E, Nuclear staining with DAPI; B, D, and F, Immunofluorescence staining with rhodamin conjugated to anti rabbit antibody. Fluorescent bacteria are seen on or between MKN-45 cells; A and B, Control group; C, D, E, and F, Cell monolayer inoculated with *H. pylori* isolate 19B and 4B, respectively (Scale bar, 200 μ m).




Figure 6. Representative SEM micrographs of 72 hour-biofilms formed by clinical isolate *H. pylori* on MKN-45 cell monolayer. Scanning electron micrographs showing cell cluster morphology(microcolony) strongly suggestive of biofilm formation. A, Control group; B and C, Cell monolayer inoculated with *H. pylori* isolate 4B and 19B, respectively.




Figure 7. Representative SEM micrographs of the MKN-45 cells infected by 19B and 4B isolates after 72 h. A, Control; B and C, Infected by 19B and 4B isolates, respectively.




Figure 8. Positions and interactions of MUC5AC and MUC1 with *H. pylori* BabA and urease. A, MUC1 as receptor and BabA as ligand; B, MUC1 as receptor and urease as ligand; C, MUC5AC as receptor and BabA as ligand; D, MUC5AC as receptor and urease as ligand. BabA, urease, MUC5AC, and MUC1 are depicted in purple, yellow, cyan, and gray, respectively. The docking score represents for each part.

5.1. Conclusions

Using an in-situ system, we showed that clinical isolates of *H. pylori* are able to form a biofilm on the human epithelial cell line, MKN-45. More detailed studies on differences of isolates with high and low abilities in biofilm formation may help understand the roles of bacterial factors

in this process. Furthermore, we observed that *H. pylori* has the ability to bind to mucin, especially MUC5AC 5AC. So, presence of mucin in our biofilm formation assay, will better correspond to the natural conditions in host.

Supplementary Material

Supplementary material(s) is available [here](#) [To read supplementary materials, please refer to the journal website and open PDF/HTML].

Footnotes

Authors' Contribution: BA and TF have designed, analyzed the experiments, and wrote the manuscript. BA performed the experiments. MK have contributed to the experimental designs and analysis. The authors read and approved the final script.

Conflict of Interests: The authors declare that they have no competing interests.

Ethical Approval: This study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments in Alzahran University. MKN45 cell line was purchase from IBRC biobank.

Funding/Support: There was no funding or support.

Informed Consent: Informed consent was taken for this study.

References

1. Cammarota G, Sanguinetti M, Gallo A, Posteraro B. Review article: biofilm formation by *Helicobacter pylori* as a target for eradication of resistant infection. *Aliment Pharmacol Ther.* 2012;36(3):222-30. doi: [10.1111/j.1365-2036.2012.05165.x](https://doi.org/10.1111/j.1365-2036.2012.05165.x). [PubMed: 22650647].
2. Dunne C, Dolan B, Clyne M. Factors that mediate colonization of the human stomach by *Helicobacter pylori*. *World J Gastroenterol.* 2014;20(19):5610-24. doi: [10.3748/wjg.v20.i19.5610](https://doi.org/10.3748/wjg.v20.i19.5610). [PubMed: 24914320]. [PubMed Central: PMC4024769].
3. Stark RM, Gerwig GJ, Pitman RS, Potts LF, Williams NA, Greenman J, et al. Biofilm formation by *Helicobacter pylori*. *Let Appl Microbiol.* 1999;28(2):121-6. doi: [10.1046/j.1365-2672.1999.00481.x](https://doi.org/10.1046/j.1365-2672.1999.00481.x).
4. Cellini L, Grande R, Traini T, Di Campi E, Di Bartolomeo S, Di Iorio D, et al. Biofilm formation and modulation of luxS and rpoD expression by *Helicobacter pylori*. *Biofilms.* 2005;2(2):119-27. doi: [10.1017/S1479050505001845](https://doi.org/10.1017/S1479050505001845).
5. Cole SP, Harwood J, Lee R, She R, Guiney DG. Characterization of monospecies biofilm formation by *Helicobacter pylori*. *J Bacteriol.* 2004;186(10):3124-32. doi: [10.1128/JB.186.10.3124-3132.2004](https://doi.org/10.1128/JB.186.10.3124-3132.2004). [PubMed: 15126474]. [PubMed Central: PMC400600].
6. Di Campi E, Di Bartolomeo S, Grande R, Di Giulio M, Cellini L. Effects of extremely low-frequency electromagnetic fields on *Helicobacter pylori* biofilm. *Curr Microbiol.* 2010;60(6):412-8. doi: [10.1007/s00284-009-9558-9](https://doi.org/10.1007/s00284-009-9558-9). [PubMed: 20033173].
7. Grande R, Di Campi E, Di Bartolomeo S, Verginelli F, Di Giulio M, Baffoni M, et al. *Helicobacter pylori* biofilm: a protective environment for bacterial recombination. *J Appl Microbiol.* 2012;113(3):669-76. doi: [10.1111/j.1365-2672.2012.05351.x](https://doi.org/10.1111/j.1365-2672.2012.05351.x). [PubMed: 22639839].
8. Yonezawa H, Osaki T, Hanawa T, Kurata S, Ochiai K, Kamiya S. Impact of *Helicobacter pylori* biofilm formation on clarithromycin susceptibility and generation of resistance mutations. *PLoS One.* 2013;8(9):e73301. doi: [10.1371/journal.pone.0073301](https://doi.org/10.1371/journal.pone.0073301). [PubMed: 24039906]. [PubMed Central: PMC3765302].
9. Carron MA, Tran VR, Sugawa C, Coticchia JM. Identification of *Helicobacter pylori* biofilms in human gastric mucosa. *J Gastrointest Surg.* 2006;10(5):712-7. doi: [10.1016/j.gassur.2005.10.019](https://doi.org/10.1016/j.gassur.2005.10.019). [PubMed: 16713544].
10. Coticchia JM, Sugawa C, Tran VR, Gurrola J, Kowalski E, Carron MA. Presence and density of *Helicobacter pylori* biofilms in human gastric mucosa in patients with peptic ulcer disease. *J Gastrointest Surg.* 2006;10(6):883-9. doi: [10.1016/j.gassur.2005.12.009](https://doi.org/10.1016/j.gassur.2005.12.009). [PubMed: 16769546].
11. Lebeaux D, Chauhan A, Rendueles O, Beloin C. From in vitro to in vivo Models of Bacterial Biofilm-Related Infections. *Pathogens.* 2013;2(2):288-356. doi: [10.3390/pathogens2020288](https://doi.org/10.3390/pathogens2020288). [PubMed: 25437038]. [PubMed Central: PMC4235718].
12. Roberts AE, Kragh KN, Bjarnsholt T, Diggle SP. The Limitations of In Vitro Experimentation in Understanding Biofilms and Chronic Infection. *J Mol Biol.* 2015;427(23):3646-61. doi: [10.1016/j.jmb.2015.09.002](https://doi.org/10.1016/j.jmb.2015.09.002). [PubMed: 26344834].
13. Salas-Jara MJ, Sanhueza EA, Retamal-Diaz A, Gonzalez C, Urrutia H, Garcia A. Probiotic *Lactobacillus fermentum* UCO-979C biofilm formation on AGS and Caco-2 cells and *Helicobacter pylori* inhibition. *Biofouling.* 2016;32(10):1245-57. doi: [10.1080/08927014.2016.1249367](https://doi.org/10.1080/08927014.2016.1249367). [PubMed: 27834106].
14. Ashrafi M, Novak-Frazer L, Bates M, Baguneid M, Alonso-Rasgado T, Xia G, et al. Validation of biofilm formation on human skin wound models and demonstration of clinically translatable bacteria-specific volatile signatures. *Sci Rep.* 2018;8(1):1-16. doi: [10.1038/s41598-018-27504-z](https://doi.org/10.1038/s41598-018-27504-z).
15. Falsafi T, Favaedi R, Mahjoub F, Najafi M. Application of stool-PCR test for diagnosis of *Helicobacter pylori* infection in children. *World J Gastroenterol.* 2009;15(4):484-8. doi: [10.3748/wjg.v15.i4.484](https://doi.org/10.3748/wjg.v15.i4.484). [PubMed: 19152455]. [PubMed Central: PMC2653372].
16. Attaran B, Falsafi T, Ghorbanmehr N. Effect of biofilm formation by clinical isolates of *Helicobacter pylori* on the efflux-mediated resistance to commonly used antibiotics. *World J Gastroenterol.* 2017;23(7):1163-70. doi: [10.3748/wjg.v23.i7.1163](https://doi.org/10.3748/wjg.v23.i7.1163). [PubMed: 28275296]. [PubMed Central: PMC532341].
17. Grande R, Di Giulio M, Bessa IJ, Di Campi E, Baffoni M, Guarnieri S, et al. Extracellular DNA in *Helicobacter pylori* biofilm: a back-stairs rumour. *J Appl Microbiol.* 2011;110(2):490-8. doi: [10.1111/j.1365-2672.2010.04911.x](https://doi.org/10.1111/j.1365-2672.2010.04911.x). [PubMed: 21143715].
18. Dheepa M. Comparision of biofilm production and multiple drug resistance in clinical isolates of *Acinetobacter baumanii* from a tertiary care hospital in South India. *Int J Pharm Biomed Sci.* 2011;2(4):103-7.
19. Attaran B, Falsafi T. Identification of Factors Associated with Biofilm Formation Ability in the Clinical Isolates of *Helicobacter pylori*. *Iran J Biotechnol.* 2017;15(1):58-66. doi: [10.1517/ijb.1368](https://doi.org/10.1517/ijb.1368). [PubMed: 28959353]. [PubMed Central: PMC5582254].
20. Falsafi T, Mahboubi M, Zargampour Z, Ahmadi M. Association between efficient adhesion to HEp-2 cells and severity of gastritis in *Helicobacter pylori* strains isolated from children. *Iran J Microbiol.* 2009;1(1):23-30.
21. Hennequin C, Porcheray F, Waligora-Dupriet A, Collignon A, Barc M, Bourlioux P, et al. GroEL (Hsp60) of *Clostridium difficile* is involved in cell adherence. *Microbiology (Reading).* 2001;147(Pt 1):87-96. doi: [10.1099/00221287-147-1-87](https://doi.org/10.1099/00221287-147-1-87). [PubMed: 11160803].
22. Falsafi T, Lavasani P, Basardeh I, Massarrat S, Landarani Z. Evaluation of an Iranian Home-made *Helicobacter pylori* Stool Antigen ELISA Kit. *Jundishapur J Microbiol.* 2014;7(6):e10629. doi: [10.5812/jjm.10629](https://doi.org/10.5812/jjm.10629). [PubMed: 25371803]. [PubMed Central: PMC4217660].

23. Rogers SL, Rogers GC. Culture of *Drosophila* S2 cells and their use for RNAi-mediated loss-of-function studies and immunofluorescence microscopy. *Nat Protoc.* 2008;3(4):606-11. doi: [10.1038/nprot.2008.18](https://doi.org/10.1038/nprot.2008.18). [PubMed: 18388942].
24. Kozakov D, Hall DR, Xia B, Porter KA, Padhorney D, Yueh C, et al. The ClusPro web server for protein-protein docking. *Nat Protoc.* 2017;12(2):255-78. doi: [10.1038/nprot.2016.169](https://doi.org/10.1038/nprot.2016.169). [PubMed: 28079879]. [PubMed Central: PMC5540229].
25. Desta IT, Porter KA, Xia B, Kozakov D, Vajda S. Performance and Its Limits in Rigid Body Protein-Protein Docking. *Structure.* 2020;28(9):1071-1081 e3. doi: [10.1016/j.str.2020.06.006](https://doi.org/10.1016/j.str.2020.06.006). [PubMed: 32649857]. [PubMed Central: PMC7484347].
26. Kozakov D, Beglov D, Bohnuud T, Mottarella SE, Xia B, Hall DR, et al. How good is automated protein docking? *Proteins.* 2013;81(12):2159-66. doi: [10.1002/prot.24403](https://doi.org/10.1002/prot.24403). [PubMed: 23996272]. [PubMed Central: PMC3934018].
27. Vajda S, Yueh C, Beglov D, Bohnuud T, Mottarella SE, Xia B, et al. New additions to the ClusPro server motivated by CAPRI. *Proteins.* 2017;85(3):435-44. doi: [10.1002/prot.25219](https://doi.org/10.1002/prot.25219). [PubMed: 27936493]. [PubMed Central: PMC5313348].
28. Meng EC, Pettersen EF, Couch GS, Huang CC, Ferrin TE. Tools for integrated sequence-structure analysis with UCSF Chimera. *BMC Bioinformatics.* 2006;7:339. doi: [10.1186/1471-2105-7-339](https://doi.org/10.1186/1471-2105-7-339). [PubMed: 16836757]. [PubMed Central: PMC1570152].
29. Rizzato C, Torres J, Kasamatsu E, Camorlinga-Ponce M, Bravo MM, Canzian F, et al. Potential Role of Biofilm Formation in the Development of Digestive Tract Cancer With Special Reference to *Helicobacter pylori* Infection. *Front Microbiol.* 2019;10:846. doi: [10.3389/fmicb.2019.00846](https://doi.org/10.3389/fmicb.2019.00846). [PubMed: 31110496]. [PubMed Central: PMC6501431].
30. Schlaermann P, Toelle B, Berger H, Schmidt SC, Glanemann M, Ordemann J, et al. A novel human gastric primary cell culture system for modelling *Helicobacter pylori* infection in vitro. *Gut.* 2016;65(2):202-13. doi: [10.1136/gutjnl-2014-307949](https://doi.org/10.1136/gutjnl-2014-307949). [PubMed: 25539675]. [PubMed Central: PMC4752654].
31. Cai J, Huang H, Song W, Hu H, Chen J, Zhang L, et al. Preparation and evaluation of lipid polymer nanoparticles for eradicating *H. pylori* biofilm and impairing antibacterial resistance in vitro. *Int J Pharm.* 2015;495(2):728-37. doi: [10.1016/j.ijpharm.2015.09.055](https://doi.org/10.1016/j.ijpharm.2015.09.055).
32. Hathroubi S, Hu S, Ottemann KM. Genetic requirements and transcriptomics of *Helicobacter pylori* biofilm formation on abiotic and biotic surfaces. *npj Biofilms Microbiomes.* 2020;6(1). doi: [10.1038/s41522-020-00167-3](https://doi.org/10.1038/s41522-020-00167-3).
33. Tan S, Tompkins LS, Amieva MR. *Helicobacter pylori* usurps cell polarity to turn the cell surface into a replicative niche. *PLoS Pathog.* 2009;5(5). e1000407. doi: [10.1371/journal.ppat.1000407](https://doi.org/10.1371/journal.ppat.1000407). [PubMed: 19412339]. [PubMed Central: PMC2669173].
34. Yonezawa H, Osaki T, Kurata S, Zaman C, Hanawa T, Kamiya S. Assessment of in vitro biofilm formation by *Helicobacter pylori*. *J Gastroenterol Hepatol.* 2010;25 Suppl 1:S90-4. doi: [10.1111/j.1440-1746.2009.06213.x](https://doi.org/10.1111/j.1440-1746.2009.06213.x). [PubMed: 20586874].
35. McAuley JL, Linden SK, Png CW, King RM, Pennington HL, Gendler SJ, et al. MUC1 cell surface mucin is a critical element of the mucosal barrier to infection. *J Clin Invest.* 2007;117(8):2313-24. doi: [10.1172/JCI26705](https://doi.org/10.1172/JCI26705). [PubMed: 17641781]. [PubMed Central: PMC1913485].
36. Perrais M, Rousseaux C, Ducourouble MP, Courcol R, Vincent P, Jonckheere N, et al. *Helicobacter pylori* urease and flagellin alter mucin gene expression in human gastric cancer cells. *Gastric Cancer.* 2014;17(2):235-46. doi: [10.1007/s10120-013-0267-5](https://doi.org/10.1007/s10120-013-0267-5). [PubMed: 23703470].
37. Linden S, Nordman H, Hedenbro J, Hurtig M, Boren T, Carlstedt I. Strain- and blood group-dependent binding of *Helicobacter pylori* to human gastric MUC5AC glycoforms. *Gastroenterology.* 2002;123(6):1923-30. doi: [10.1053/gast.2002.37076](https://doi.org/10.1053/gast.2002.37076). [PubMed: 12454849].
38. Guang W, Czinn SJ, Blanchard TG, Kim KC, Lillehoj EP. Genetic regulation of MUC1 expression by *Helicobacter pylori* in gastric cancer cells. *Biochem Biophys Res Commun.* 2014;445(1):145-50. doi: [10.1016/j.bbrc.2014.01.142](https://doi.org/10.1016/j.bbrc.2014.01.142). [PubMed: 24491543]. [PubMed Central: PMC3964589].
39. Niv Y. *Helicobacter pylori* and gastric mucin expression: A systematic review and meta-analysis. *World J Gastroenterol.* 2015;21(31):9430-6. doi: [10.3748/wjg.v21.i31.9430](https://doi.org/10.3748/wjg.v21.i31.9430). [PubMed: 26309370]. [PubMed Central: PMC4541396].
40. Linden SK, Wickstrom C, Lindell G, Gilshenan K, Carlstedt I. Four modes of adhesion are used during *Helicobacter pylori* binding to human mucins in the oral and gastric niches. *Helicobacter.* 2008;13(2):81-93. doi: [10.1111/j.1523-5378.2008.00587.x](https://doi.org/10.1111/j.1523-5378.2008.00587.x). [PubMed: 18321298].
41. Matsuda K, Yamauchi K, Matsumoto T, Sano K, Yamaoka Y, Ota H. Quantitative analysis of the effect of *Helicobacter pylori* on the expressions of SOX2, CDX2, MUC2, MUC5AC, MUC6, TFF1, TFF2, and TFF3 mRNAs in human gastric carcinoma cells. *Scand J Gastroenterol.* 2008;43(1):25-33. doi: [10.1080/00365520701579795](https://doi.org/10.1080/00365520701579795). [PubMed: 18938748]. [PubMed Central: PMC3128253].
42. Linden SK, Driessen KM, McGuckin MA. Improved in vitro model systems for gastrointestinal infection by choice of cell line, pH, microaerobic conditions, and optimization of culture conditions. *Helicobacter.* 2007;12(4):341-53. doi: [10.1111/j.1523-5378.2007.00509.x](https://doi.org/10.1111/j.1523-5378.2007.00509.x). [PubMed: 17669108].